Tridem Pharma

Tridem Pharma is a pharmaceutical company focusing on healthcare solutions, particularly in the African and Middle Eastern markets. They provide a range of products including antimalarial medications and consumer health items. Founded in 1986 and headquartered in France, Tridem Pharma specializes in pharmaceutical distribution and healthcare products. The company was acquired by Fosun Pharma in a Trade Sale valued at EUR 63 million in October 2017.

Tridem Pharma has completed a total of 2 deals in its operational history. Tridem Pharma specializes in providing a comprehensive range of pharmaceutical and healthcare products, focusing on the African and Middle Eastern markets. Their core offerings include antimalarial medications, consumer health products, and services related to pharmaceutical distribution. The company has established strong relationships with international procurement agencies and local wholesalers, ensuring a robust supply chain that addresses the healthcare needs of public sector medical stores and private sector distributors alike.

By leveraging their extensive distribution network, which spans over 35 countries, Tridem Pharma effectively delivers tailor-made business solutions that aid companies in expanding their operations and enhancing access to healthcare solutions across various regions. Key markets for their products include Ghana, Kenya, Nigeria, and Tanzania, as well as several French-speaking countries in Africa. In the most recent fiscal year of 2023, Tridem Pharma reported a revenue of EUR 213,663,184. 60 and an EBITDA of EUR 3,595,046.

50. The company generates revenue primarily through B2B transactions with local distributors and wholesalers, maintaining a steady supply of pharmaceutical products to government health agencies and private healthcare providers. Tridem Pharma plans to expand its product offerings and enter new markets in the coming years. The company is actively designing new healthcare solutions aimed at enhancing its portfolio.

Recent funding from Fosun Pharma will be utilized to support the development of these upcoming products and facilitate entry into new geographical regions by 2025, targeting key markets in West and East Africa to further broaden their reach.